公开(公告)号：US07238690B2

公开(公告)日：2007-07-03

申请号：US11375935

申请日：2006-03-15

申请人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Wenting Chen ,  Christopher D. McClung ,  Emilie J. Calvello ,  David M. Zawrotny

发明人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Wenting Chen ,  Christopher D. McClung ,  Emilie J. Calvello ,  David M. Zawrotny

IPC分类号： C07D491/16 ,  A61K31/5383

CPC分类号： C07D471/06 ,  C07D221/18 ,  C07D223/32 ,  C07D491/06 ,  C07D495/06

摘要： The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

摘要翻译： 本发明涉及可用于治疗由结构式（I）或其药学上可接受的盐形式表示的成瘾行为和睡眠障碍的化合物，其中R 1，R 5， R 6a，R 6b，R 7，R 8，R 9， X，b，k，m和n，这里描述虚线。 用于治疗本发明的方法中的化合物是血清素激动剂和拮抗剂，并且可用于控制或预防中枢神经系统疾病，包括上瘾行为和睡眠障碍。

公开(公告)号：USRE39679E1

公开(公告)日：2007-06-05

申请号：US11356423

申请日：2006-02-16

申请人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Michael Guang Yang ,  Simon Haydar ,  Wenting Chen ,  Christopher D. McClung ,  Emile J. B. Calvello ,  David M. Zawrotny ,  Parthasarathl Rajagopalan

发明人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Michael Guang Yang ,  Simon Haydar ,  Wenting Chen ,  Christopher D. McClung ,  Emile J. B. Calvello ,  David M. Zawrotny ,  Parthasarathl Rajagopalan

IPC分类号： C07D267/22 ,  C07D281/18 ,  C07D267/02 ,  C07D279/00 ,  C07D265/34

CPC分类号： C07D471/06 ,  C07D221/18 ,  C07D223/32 ,  C07D491/06 ,  C07D495/06

摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

公开(公告)号：US06548493B1

公开(公告)日：2003-04-15

申请号：US09594008

申请日：2000-06-15

申请人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Wenting Chen ,  Christopher D. McClung ,  Emilie J. B. Calvello ,  David M. Zawrotny

发明人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Wenting Chen ,  Christopher D. McClung ,  Emilie J. B. Calvello ,  David M. Zawrotny

IPC分类号： C07D51316

CPC分类号： C07D471/06 ,  C07D221/18 ,  C07D223/32 ,  C07D491/06 ,  C07D495/06

摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

公开(公告)号：US07081455B2

公开(公告)日：2006-07-25

申请号：US10786935

申请日：2004-02-25

申请人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Wenting Chen ,  Christopher D. McClung ,  Emilie J. Calvello ,  David M. Zawrotny

发明人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Wenting Chen ,  Christopher D. McClung ,  Emilie J. Calvello ,  David M. Zawrotny

IPC分类号： A61P25/00

CPC分类号： C07D471/06 ,  C07D221/18 ,  C07D223/32 ,  C07D491/06 ,  C07D495/06

摘要： The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

摘要翻译： 本发明涉及通过施用由结构式（I）表示的化合物或其药学上可接受的盐形式来治疗成瘾行为和睡眠障碍的方法，其中R 1，R 5， R 6a，R 6b，R 7，R 8，R 9，R 9， >，X，b，k，m和n，这里描述虚线。 用于治疗本发明的方法中的化合物是血清素激动剂和拮抗剂，并且可用于控制或预防中枢神经系统疾病，包括上瘾行为和睡眠障碍。

公开(公告)号：US06713471B1

公开(公告)日：2004-03-30

申请号：US09594954

申请日：2000-06-15

申请人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Simon Haydar ,  Wenting Chen ,  Christopher D. Mc Clung ,  Emilie J. B. Calvello ,  David M. Zawrotny

发明人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Simon Haydar ,  Wenting Chen ,  Christopher D. Mc Clung ,  Emilie J. B. Calvello ,  David M. Zawrotny

IPC分类号： C07D26722

CPC分类号： C07D471/06 ,  C07D221/18 ,  C07D223/32 ,  C07D491/06 ,  C07D495/06

摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

摘要翻译： 本发明涉及由结构式（I）表示的某些新化合物或其药学上可接受的盐形式，其中R 1，R 5，R 6a，R 6b，R 7，R 7， <8>，R 9，X，b，k，m和n，这里描述虚线。 本发明还涉及包含这些新化合物作为活性成分的药物制剂，以及新型化合物及其制剂在治疗某些疾病中的用途。 本发明的化合物是血清素激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠障碍，性障碍，偏头痛，与头痛相关的病症，社交恐怖症 ，以及胃肠道疾病如胃肠道运动功能障碍。

公开(公告)号：US06552017B1

公开(公告)日：2003-04-22

申请号：US09595250

申请日：2000-06-15

申请人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Michael Guang Yang ,  Simon Haydar ,  Wenting Chen ,  Christopher D. Mc Clung ,  Emilie J. B. Calvello ,  David M. Zawrotny

发明人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Michael Guang Yang ,  Simon Haydar ,  Wenting Chen ,  Christopher D. Mc Clung ,  Emilie J. B. Calvello ,  David M. Zawrotny

IPC分类号： C07D48700

CPC分类号： C07D471/06 ,  C07D221/18 ,  C07D223/32 ,  C07D491/06 ,  C07D495/06

摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

摘要翻译： 本发明涉及由结构式（I）表示的某些新化合物或其药学上可接受的盐形式，其中R1，R5，R6a，R6b，R7，R8，R9，X，b，k，m和n以及 这里描述了虚线。 本发明还涉及包含这些新化合物作为活性成分的药物制剂，以及新型化合物及其制剂在治疗某些疾病中的用途。 本发明的化合物是血清素激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠障碍，性障碍，偏头痛，与头痛相关的病症，社交恐怖症 ，以及胃肠道疾病如胃肠道运动功能障碍。

公开(公告)号：USRE39680E1

公开(公告)日：2007-06-05

申请号：US11356421

申请日：2006-02-16

申请人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Michael Guang Yang ,  Simon Haydar ,  Wenting Chen ,  Christopher D. McClung ,  Emile J. B. Calvello ,  David M. Zawrotny ,  Parthasarathl Rajagopalan

发明人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Michael Guang Yang ,  Simon Haydar ,  Wenting Chen ,  Christopher D. McClung ,  Emile J. B. Calvello ,  David M. Zawrotny ,  Parthasarathl Rajagopalan

IPC分类号： C07D487/00 ,  C07D243/00 ,  C07D491/00 ,  C07D241/36 ,  A61K31/55

CPC分类号： C07D471/06 ,  C07D221/18 ,  C07D223/32 ,  C07D491/06 ,  C07D495/06

摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

摘要翻译： 本发明涉及由结构式（I）表示的某些新化合物或其药学上可接受的盐形式，其中R 1，R 5，R 6， R 6b，R 6b，R 7，R 8，R 9，X，b，k， m和n，虚线在此描述。 本发明还涉及包含这些新化合物作为活性成分的药物制剂，以及新型化合物及其制剂在治疗某些疾病中的用途。 本发明的化合物是血清素激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠障碍，性障碍，偏头痛，与头痛相关的病症，社交恐怖症 ，以及胃肠道疾病如胃肠道运动功能障碍。

公开(公告)号：US07183282B2

公开(公告)日：2007-02-27

申请号：US11375125

申请日：2006-03-14

申请人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Michael G. Yang ,  Simon Haydar ,  Wenting Chen ,  Christopher D. McClung ,  Emilie J. Calvello ,  David M. Zawrotny

发明人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Michael G. Yang ,  Simon Haydar ,  Wenting Chen ,  Christopher D. McClung ,  Emilie J. Calvello ,  David M. Zawrotny

IPC分类号： C07D471/04 ,  A61K31/4985

CPC分类号： C07D471/06 ,  C07D221/18 ,  C07D223/32 ,  C07D471/16 ,  C07D487/06 ,  C07D491/06 ,  C07D495/06 ,  C07D513/06 ,  C07D513/16 ,  C07D519/00

摘要： The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

公开(公告)号：US07071186B2

公开(公告)日：2006-07-04

申请号：US10787941

申请日：2004-02-26

申请人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Michael G. Yang ,  Simon Haydar ,  Wenting Chen ,  Christopher D. McClung ,  Emilie J. Calvello ,  David M. Zawrotny

发明人： Albert J. Robichaud ,  Taekyu Lee ,  Wei Deng ,  Ian S. Mitchell ,  Michael G. Yang ,  Simon Haydar ,  Wenting Chen ,  Christopher D. McClung ,  Emilie J. Calvello ,  David M. Zawrotny

IPC分类号： A61P25/00

CPC分类号： C07D471/06 ,  C07D221/18 ,  C07D223/32 ,  C07D471/16 ,  C07D487/06 ,  C07D491/06 ,  C07D495/06 ,  C07D513/06 ,  C07D513/16 ,  C07D519/00

摘要： The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.